Business
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform Agreement provides for Parabilis to receive $125M from Regeneron, consisting of a $50M upfront payment and $75M equity commitment, with up to approximately $2.2B in additional potential milestone payments plus tiered royalties TARRYTOWN, N.Y., May 18, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a strategic research
About this update from Regeneron Pharmaceuticals, Inc.
[{"type":"image","alt":"Regeneron Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Regeneron Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":47,"url":"https://media.zenfs.com/en/globenewswire.com/dd48a84a10e2c569a1750589118f2d19"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YS4R8ksqsw0QmsiNDKmPPw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY2/https://media.zenfs.com/en/globenewswire.com/dd48a84a10e2c569a1750589118f2d19","width":300,"height":47},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/YS4R8ksqsw0QmsiNDKmPPw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY2/https://media.zenfs.com/en/globenewswire.com/dd48a84a10e2c569a1750589118f2d19","width":300,"height":47}},"lazy":false},{"type":"text","content":"The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform ","length":138,"tagName":"p"},{"type":"text","content":"Agreement provides for Parabilis to receive $125M from Regeneron, consisting of a $50M upfront payment and $75M equity commitment, with up to approximately $2.2B in additional potential milestone payments plus tiered royalties","length":226,"tagName":"p"},{"type":"text","content":"TARRYTOWN, N.Y., May 18, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a strategic research collaboration with Parabilis Medicines to discover and develop multiple therapeutic candidates based on Parabilis’ Helicon™ peptide platform, with a particular focus on Antibody-Helicon™ Conjugates (AHCs), a novel class of therapeutics designed to target challenging and historically “undruggable” targets. Helicons are stabilized, cell-penetrant alpha-helical peptides designed to engage intracellular protein targets, including flat surfaces not well suited to traditional small molecule binding. The collaboration is designed to explore the use of Helicons both as stand-alone therapies and as part of AHCs.","length":758,"tagName":"p"},{"type":"text","content":"“This collaboration reflects Regeneron’s approach of advancing cutting-edge and diversified science to produce a robust portfolio of innovative medicines for patients in need,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer of Regeneron. “In addition to the pote...